Skip to main content

Photoacoustic/Ultrasound Mammoscopy for evaluating screening-detected abnormalities in the breast

Objective

X-ray mammography is the mainstay of breast cancer screening programs. It is estimated that between 20 - 50% of abnormal screening mammograms will prove to be negative. The paradigm in diagnosis is to establish whether a lesion is benign or malignant. All the imaging techniques conventionally used today – diagnostic x-ray, ultrasonography and magnetic resonance imaging have many limitations, leading to multiple and/or repeat imaging and often unnecessary biopsy. This leads to physical, psychological and economic burdens felt at individual, familial and societal levels.

With an aging population, high incidence of breast cancer and tightening health-care budgets, there is an urgent requirement for a non-invasive method for in-depth assessment of the screening-detected lesion. In PAMMOTH we will showcase such an imager, combining photoacoustic and ultrasound imaging. With the use of quantitative image reconstruction of multi-wavelength photoacoustic data, information is gained of the vascular and oxygen status of the lesion relating to tumor physiology and function. From the ultrasound part, we derive ultrasound reflection from the lesion in a manner superior to conventional breast ultrasonography, relating to anatomic features and extent of a tumor. This information will enable the radiologist to come to a diagnosis accurately and rapidly without the use of contrast agents, without pain and discomfort to the patient, while being cost-effective and not requiring complex infrastructure.

Four excellent academic groups, three dynamic SMEs, and a hospital come together with support from key stakeholders in an Advisory group, to push beyond the state-of-the-art in science and technology to achieve the PAMMOTH imager. For the SMEs, in addition to tremendous improvements in individual product lines, the new integrated diagnostic imaging instrument opens up completely new market opportunities.

We expect PAMMOTH to have a strong economic and clinical impact.

Call for proposal

H2020-ICT-2016-1
See other projects for this call

Funding Scheme

RIA - Research and Innovation action

Coordinator

UNIVERSITEIT TWENTE
Address
Drienerlolaan 5
7522 NB Enschede
Netherlands
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 864 375

Participants (8)

PA IMAGING R&D BV
Netherlands
EU contribution
€ 816 000
Address
Drienerlolaan 5
7522 NB Enschede
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
STICHTING MEDISCH SPECTRUM TWENTE
Netherlands
EU contribution
€ 185 000
Address
Haaksbergerstraat 55
7513 ER Enschede
Activity type
Other
UNIVERSITY COLLEGE LONDON
United Kingdom
EU contribution
€ 708 663,75
Address
Gower Street
WC1E 6BT London
Activity type
Higher or Secondary Education Establishments
UNIVERSITAET BERN
Switzerland
EU contribution
€ 0
Address
Hochschulstrasse 6
3012 Bern
Activity type
Higher or Secondary Education Establishments
VYSOKE UCENI TECHNICKE V BRNE
Czechia
EU contribution
€ 385 000
Address
Antoninska 548/1
601 90 Brno Stred
Activity type
Higher or Secondary Education Establishments
IMASONIC SAS
France
EU contribution
€ 760 000
Address
Za Rue Des Savourots
70190 Voray Sur L'ognon
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
EKSPLA UAB
Lithuania
EU contribution
€ 410 468,75
Address
Savanoriu Pr 231
02300 Vilnius
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
TP21 GMBH
Germany
EU contribution
€ 222 500
Address
Luisenstrasse 14
10117 Berlin
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)